Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Metrics to compare | MTLF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMTLFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −2.2x | −0.5x | |
PEG Ratio | 0.06 | −0.10 | 0.00 | |
Price/Book | 9.1x | 1.2x | 2.6x | |
Price / LTM Sales | - | 8.0x | 3.2x | |
Upside (Analyst Target) | - | 882.9% | 43.6% | |
Fair Value Upside | Unlock | 5.9% | 4.9% | Unlock |